Home / VEGF-C / Recombinant Human VEGF-C (Cys156Ser) Protein

Recombinant Human VEGF-C (Cys156Ser) Protein

Catalog #: 752-VC
22 Citations Datasheet

Carrier Free

Catalog # Availability Size / Price Qty
752-VC-025/CF

With Carrier

Catalog # Availability Size / Price Qty
752-VC-025
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (22)
FAQs
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VEGF-C (Cys156Ser) Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96:9671. The ED50 for this effect is 1-5 µg/mL. Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGF R3/Flt‑4 Fc Chimera (Catalog # 349-F4) at 5 µg/mL (100 µL/well) can bind  Recombinant Human VEGF‑C (Cys156Ser) with an apparent Kd <40 nM.
Source
Mouse myeloma cell line, NS0-derived human VEGF-C protein
Thr103-Arg227 (Cys156Ser), with a C-terminal 10-His tag
Accession #
Q6FH59
N-terminal Sequence
Analysis
Thr103
Predicted Molecular Mass
15.4 kDa
SDS-PAGE
22-24 kDa, reducing conditions

Product Datasheets

You must select a language.

x

752-VC (with carrier)

Product Datasheet

You must select a language.

x

752-VC/CF (carrier free)

Product Datasheet

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

752-VC

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

752-VC/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGF-C

Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors (1). VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4 (2-4). Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1 (2, 4). Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis (5-8). VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes (9-12). It also induces physiological and intratumoral neoangiogenesis and vessel sprouting through interactions with VEGF R2 (8, 13, 14).

References
  1. Chen, J.-C. et al. (2013) Int. J. Mol. Sci. 14:88.
  2. Joukov, V. et al. (1996) EMBO J. 15:290.
  3. Kukk, E. et al. (1996) Development 122:3829.
  4. Joukov, V. et al. (1997) EMBO J. 16:3898.
  5. Karkkainen, M. et al. (2004) Nat. Immunol. 5:74.
  6. Jeltsch, M. et al. (1997) Science 276:1423.
  7. Makinen, T. et al. (2001) Nat. Med. 7:199.
  8. Laakkonen, P. et al. (2007) Cancer Res. 67:593.
  9. Hoshida, T. et al. (2006) Cancer Res. 66:8065.
  10. Mandriota, S.J. et al. (2001) EMBO J. 20:672.
  11. Skobe, M. et al. (2001) Nat. Med. 7:192.
  12. Padera, T.P. et al. (2002) Science 296:1883.
  13. Tammela, T. et al. (2008) Nature 454:656.
  14. Cao, Y. et al. (1998) Proc. Natl. Acad. Sci. 95:14389.
Long Name
Vascular Endothelial Growth Factor C
Entrez Gene IDs
7424 (Human); 22341 (Mouse)
Alternate Names
Flt4 ligand; Flt4-L; vascular endothelial growth factor C; Vascular endothelial growth factor-related protein; VEGFC; VEGF-C; VRPFLT4 ligand DHM

Citations for Recombinant Human VEGF-C (Cys156Ser) Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

22 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Alkali injury-induced pathological lymphangiogenesis in the iris facilitates the infiltration of T cells and ocular inflammation
    Authors: Liu, Z;Liu, K;Shi, S;Chen, X;Gu, X;Wang, W;Mao, K;Yibulayi, R;Wu, W;Zeng, L;Zhou, W;Lin, X;Zhang, F;Lou, B;
    JCI insight
    Species: Mouse, Transgenic Mouse
    Sample Types: In Vivo
    Applications: In vivo assay
  2. Lymphatic platelet thrombosis limits bone repair by precluding lymphatic transporting DAMPs
    Authors: Wang, YJ;Zheng, Y;Cong, L;Wang, P;Zhao, L;Xing, L;Liu, J;Xu, H;Li, N;Zhao, Y;Shi, Q;Liang, Q;
    Research square
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  3. Dual role of Vascular Endothelial Growth Factor-C (VEGF-C) in post-stroke recovery
    Authors: Choi, YH;Hsu, M;Laaker, C;Herbath, M;Yang, H;Cismaru, P;Johnson, AM;Spellman, B;Wigand, K;Sandor, M;Fabry, Z;
    bioRxiv : the preprint server for biology
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  4. SAR131675 exhibits anticancer activity on human ovarian cancer cells through inhibition of VEGFR-3/ERK1/2/AKT signaling pathway
    Authors: Babaei, Z;Panjehpour, M;Parsian, H;Aghaei, M;
    Cellular signalling
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer
    Authors: S Dutta, NS Polavaram, R Islam, S Bhattachar, S Bodas, T Mayr, S Roy, SAY Albala, MI Toma, A Darehshour, A Borkowetz, S Conrad, S Fuessel, M Wirth, GB Baretton, LC Hofbauer, P Ghosh, KJ Pienta, DL Klinkebiel, SK Batra, MH Muders, K Datta
    Oncogene, 2022-06-27;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Chronic VEGFR-3 signaling preserves dendritic arborization and sensitization under stress
    Authors: A Chakrabort, R Upadhya, TA Usman, AK Shetty, JM Rutkowski
    Brain, Behavior, and Immunity, 2021-08-11;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Impact of Lymphangiogenesis on Cardiac Remodeling After Ischemia and Reperfusion Injury
    Authors: Y Shimizu, R Polavarapu, KL Eskla, Y Pantner, CK Nicholson, M Ishii, D Brunnhoelz, R Mauria, A Husain, N Naqvi, T Murohara, JW Calvert
    J Am Heart Assoc, 2018-10-02;7(19):e009565.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction
    Authors: JM Vieira, S Norman, C Villa Del, TJ Cahill, DN Barnette, M Gunadasa-R, LA Johnson, DR Greaves, CA Carr, DG Jackson, PR Riley
    J. Clin. Invest., 2018-07-09;0(0):.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  9. Induced dural lymphangiogenesis facilities soluble amyloid-beta clearance from brain in a transgenic mouse model of Alzheimer's disease
    Authors: YR Wen, JH Yang, X Wang, ZB Yao
    Neural Regen Res, 2018-04-01;13(4):709-716.
    Species: Human, Mouse
    Sample Types: In Vivo, Whole Cells
    Applications: Bioassay, In Vivo
  10. Biology of Vascular Endothelial Growth Factor C in the Morphogenesis of Lymphatic Vessels
    Authors: K Rauniyar, SK Jha, M Jeltsch
    Front Bioeng Biotechnol, 2018-02-12;6(0):7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  11. Structural and functional features of central nervous system lymphatic vessels.
    Authors: Louveau A, Smirnov I, Keyes T, Eccles J, Rouhani S, Peske J, Derecki N, Castle D, Mandell J, Lee K, Harris T, Kipnis J
    Nature, 2015-06-01;523(7560):337-41.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  12. Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis.
    Authors: Heishi T, Hosaka T, Suzuki Y, Miyashita H, Oike Y, Takahashi T, Nakamura T, Arioka S, Mitsuda Y, Takakura T, Hojo K, Matsumoto M, Yamauchi C, Ohta H, Sonoda H, Sato Y
    Am. J. Pathol., 2010-02-04;176(4):1950-8.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  13. Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway.
    Authors: Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML
    Carcinogenesis, 2009-12-01;30(12):2005-13.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis.
    Authors: Kajiya K, Sawane M, Huggenberger R, Detmar M
    J. Invest. Dermatol., 2008-11-13;129(5):1292-8.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  15. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.
    Authors: Shin JW, Huggenberger R, Detmar M
    Blood, 2008-07-09;112(6):2318-26.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  16. The resolution of lymphedema by interstitial flow in the mouse tail skin.
    Authors: Uzarski J, Drelles MB, Gibbs SE, Ongstad EL, Goral JC, McKeown KK, Raehl AM, Roberts MA, Pytowski B, Smith MR, Goldman J
    Am. J. Physiol. Heart Circ. Physiol., 2008-01-18;294(3):H1326-34.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  17. Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1.
    Authors: Kilic N, Oliveira-Ferrer L, Neshat-Vahid S, Irmak S, Obst-Pernberg K, Wurmbach JH, Loges S, Kilic E, Weil J, Lauke H, Tilki D, Singer BB, Ergun S
    Blood, 2007-08-30;110(13):4223-33.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  18. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
    Authors: Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, Huss R, Graeb C, Jauch KW, Heeschen C, Guba M
    Kidney Int., 2007-02-14;71(8):771-7.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  19. Regulation of lymphatic capillary regeneration by interstitial flow in skin.
    Authors: Goldman J, Conley KA, Raehl A, Bondy DM, Pytowski B, Swartz MA, Rutkowski JM, Jaroch DB, Ongstad EL
    Am. J. Physiol. Heart Circ. Physiol., 2006-12-22;292(5):H2176-83.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  20. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain.
    Authors: Le Bras B, Barallobre MJ, Homman-Ludiye J, Ny A, Wyns S, Tammela T, Haiko P, Karkkainen MJ, Yuan L, Muriel MP, Chatzopoulou E, Breant C, Zalc B, Carmeliet P, Alitalo K, Eichmann A, Thomas JL
    Nat. Neurosci., 2006-02-05;9(3):340-8.
    Species: Mouse, Xenopus
    Sample Types: Whole Cells
    Applications: Bioassay
  21. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis.
    Authors: Shin JW, Min M, Larrieu-Lahargue F, Canron X, Kunstfeld R, Nguyen L, Henderson JE, Bikfalvi A, Detmar M, Hong YK
    Mol. Biol. Cell, 2005-11-16;17(2):576-84.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  22. Loss of Tie2 receptor compromises embryonic stem cell-derived endothelial but not hematopoietic cell survival.
    Authors: Hamaguchi I, Morisada T, Azuma M, Murakami K, Kuramitsu M, Mizukami T, Ohbo K, Yamaguchi K, Oike Y, Dumont DJ, Suda T
    Blood, 2005-10-11;107(3):1207-13.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human VEGF-C (Cys156Ser) Protein

There are currently no reviews for this product. Be the first to review Recombinant Human VEGF-C (Cys156Ser) Protein and earn rewards!

Have you used Recombinant Human VEGF-C (Cys156Ser) Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review